BRISTOL-MYERS SQUIBB COMPANY for BRISTOL-MYERS SQUIBB COMPANY
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Copyright/Patent/Trademark CPT
Intellectual Property Reform concerning bio-pharmaceutical industry. No related bill number
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Health Issues HCR
HR 1319 - American Rescue Plan Act of 2021 - regarding all bio-pharmaceutical related provisions S 464 - Safe Step Act - regarding all bio-pharmaceutical related provisions Issues related to the Reauthorization of the Prescription Drug User Fee Act (PDUFA) - regarding all bio-pharmaceutical related provisions. No bill number Issues related to the 340B Drug Pricing Program - regarding all bio-pharmaceutical related provisions. No bill number. Issues Related to the Food and Drug Administration's accelerated approval process - regarding all bio-pharmaceutical related provisions. No bill number. H.R 4385 - Cancer Drug Parity Act/Oral Parity - regarding all bio-pharmaceutical related provisions. E- Prescribing Information- regarding modernizing the distribution of prescribing information. No bill number Issues related to access and reimbursement of Chimeric Antigen Receptor Therapy (CAR T). No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Medicare/Medicaid MMM
H.R 2071 - To amend Part D of title XVIII of the Social Security Act to require the Secretary of health and Human Services to negotiate covered Part D drug prices on behalf of Medicare beneficiaries - regarding all bio-pharmaceutical related provisions. S.908/H.R 2139 - A bill to amend title XVII of the Social Security Act to provide for the negotiation of lower covered Part D drug prices on behalf of Medicare beneficiaries and the establishment and application of a formulary by the Secretary of Health and Human Services under Medicare Part D, and for other purposes - regarding all bio-pharmaceutical related provisions. H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| THOMAS BRUNET | — |
| JOHN DEOUDES | — |
| STEPHANIE A. DYSON | — |
| KATHRYN NOVARIA | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Trade (domestic/foreign) TRD
International Reference Pricing/Most Favored Nation regarding all bio-pharmaceutical related issues. No bill number. Essential Medicines/Buy American - regarding all bio-pharmaceutical related provisions. No bill number. Trade-Related Aspects of Intellectual Property (TRIPS) Waiver. No related bill number. S.1854, the National Critical Capabilities Act of 2021 - regarding all bio-pharmaceutical related provisions
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
| LANE PENRY | — |
| RICARDO SANCHEZ ORTEGON | — |
| PAUL ANTHONY WILLIAMS | — |
Taxation/Internal Revenue Code TAX
Proposed policies regarding corporate tax reform - regarding all bio-pharmaceutical related provisions. H.R.1304- American Innovation and R&D Competitiveness Act of 2021 H.R 5376, the Build Back Better Act - regarding all bio-pharmaceutical related provisions and corporate tax provisions.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JOHN DEOUDES | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.